Filippo Montemurro
@FilippoMontemu1
Followers
2K
Following
2K
Media
51
Statuses
2K
Senior Medical Director, F. Hoffmann La Roche
Basel, Switzerland
Joined November 2018
A Life on the Line and $250K in Medical Debt Amid Insurer Denials The battle of bots…always saddened by this type stories☹️😔.
0
0
1
This is interesting. By binding to NK1R, the P protein can affect several aspects of cancer hallmarks. This intriguing article suggests an anticaner role for NK1R inhibitors commonly used to treat severe nausea an vomiting due to chemotherapy.
pubmed.ncbi.nlm.nih.gov
Aprepitant use during chemotherapy treatment was associated with better prognosis for women with non-luminal early breast cancer, in particular TNBC. Long-term clinical trials are required to confirm...
0
3
8
Microenvironmental differences may account for the different outcomes of breast cancer in black vs white Americans? Need to give this a "slow reading". Most important, are these druggable?
pubmed.ncbi.nlm.nih.gov
Racial disparities in the clinical outcomes of triple-negative breast cancer (TNBC) have been well-documented, but the underlying biological mechanisms remain poorly understood. To investigate these...
1
0
2
In the clinic, only 4.3% of patients with a positive test will have breast cancer at 90% SN and SP, and if those could be pushed to 99%, the figure would be 33%. This is because the baseline prevalence of the condition that the test targets is part of the PPV equation.
1
0
0
The graph I have generate depicts two tests differing in SN and SP (90 and 99) and three situations, the first representing the real prevalence of breast cancer in the population that is the subject of the screening 0.5%). While in experimental conditions a test can perform super.
1
0
0
New Mammography Tools — The Need for Clinically Meaningful Assessment Standards | A must-read editorial in NEJM. A memento that prevalences that are used in samples to develop new tests may be far from the real prevalence in the clinic.
nejm.org
AI mammography aids are being sold as additions to mammography screening, with direct-to-consumer marketing touting improved cancer-detection rates, despite a lack of evidence of clinical effective...
1
0
0
RT @CharlesSwanton: 1/11 Our study on subclonal immune evasion in non-small cell lung cancer has just been published in @Cancer_Cell . http….
cell.com
Dijkstra et al. investigate whether individual cancer subclones differ in their immune evasion capacity. They establish organoids representing distinct subclones from multi-region lung cancer...
0
111
0
Breastfeeding after breast cancer in young BRCA carriers This one too, for BRCA carriers.
academic.oup.com
AbstractBackground. We investigated safety of breastfeeding after breast cancer in patients carrying germline BRCA pathogenic or likely pathogenic variants
0
0
1
Breastfeeding After Hormone Receptor–Positive Breast Cancer: Results From the POSITIVE Trial | Journal of Clinical Oncology Another valuable info from the POSITIVE trial.
ascopubs.org
PURPOSEWe investigated breastfeeding patterns, behaviors, and association with breast cancer (BC) outcomes in women with early hormone receptor–positive (HR+) BC who had a live birth in the POSITIVE...
0
0
1
Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast. The old issue of AIs being detrimental for cardiovascular health is rediscussed in this nice paper. AIs seem to reduce cardiovascular morbidity and mortality.
academic.oup.com
AbstractBackground. There are increasing concerns of cardiovascular safety related to endocrine therapy use in women with breast cancer (BC). We examined r
0
1
3
RT @drsarahsam: Exercise is medicine. Physically active breast cancer survivors had 31% (95% CI: 25–37%) reduction in risk of breast can….
pmc.ncbi.nlm.nih.gov
Cancer remains a major global health challenge, and growing evidence suggests that physical activity is a key modifiable factor that may improve survival outcomes in cancer patients. However, a...
0
26
0
In my opinion, this is the best reading of the year so far (at least for me). Worthy of a "Slow reading". KUDOS to the authors.
nature.com
Nature Medicine - Multi-omic single-cell and spatial analyses of lung cancer brain metastases from multiple cohorts identify high levels of chromosomal instability and a neural-like profile in...
0
0
3
Conoccurring mutations in GATA3 mut tumors may reveal actionable targets in HR+ resistant tumors. Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes - PubMed
pubmed.ncbi.nlm.nih.gov
The distinct landscape in GATA3mut MBC ctDNA highlights critical information when assessing candidacy for targeted therapies. To our knowledge, this is the first ctDNA-based GATA3mut landscape...
1
5
10
A Multi-Institutional Analysis of Contralateral Axillary Metastases: Advanced Local-Regional Disease Divergent from Stage IV Breast Cancer - PubMed A nice paper on a clinical dilemma
pubmed.ncbi.nlm.nih.gov
Survival was higher for patients with CAM compared with MBC and was similar to patients with LABC. Though the LABC group demonstrated better recurrence-free survival than the CAM group, these numbers...
0
1
2
This looks promising. for sure, worthy of a "slow reading".
DESTINY-Breast09: First-line T-DXd + pertuzumab significantly prolongs PFS vs THP in HER2+ mBC:.40.7 vs 26.9 mo (HR 0.56; P<.00001)‼️.New first-line standard?.Led by @stolaney1 and discussed by @claudine_isaacs at #ASCO25 #BreastCancer .➡️
0
0
1
Interesting analysis from I-SPY investigators. Although nonsignificant, the negative prognostic impact of cT 3/4 at diagnosis in HER2-positive patients achieving pCR is consistent with other studies.
pubmed.ncbi.nlm.nih.gov
I-SPY 2 TRIAL beginning December 31, 2009: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY 2), NCT01042379.
0
4
10
RT @NEJMEvidence: Review Article: “Reading and Interpreting Quality-of-Life Results in Cancer Trials” by @MassimoDiMaio75: .
0
19
0